About nrx pharmaceuticals inc - NRXP
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.
NRXP At a Glance
NRX Pharmaceuticals, Inc.
1201 Orange Street
Wilmington, Delaware 19801
| Phone | 1-484-254-6134 | Revenue | 1.23M | |
| Industry | Pharmaceuticals: Major | Net Income | -28,622,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NRXP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 47.346 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.168 |
| Enterprise Value to Sales | 41.496 |
| Total Debt to Enterprise Value | 0.012 |
NRXP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 7.609 |
| Total Asset Turnover | 0.148 |
NRXP Liquidity
| Current Ratio | 0.311 |
| Quick Ratio | 0.311 |
| Cash Ratio | 0.273 |
NRXP Profitability
| Gross Margin | 47.102 |
| Operating Margin | -1,321.469 |
| Pretax Margin | -2,336.49 |
| Net Margin | -2,336.49 |
| Return on Assets | -344.698 |
| Return on Equity | N/A |
| Return on Total Capital | 186.999 |
| Return on Invested Capital | N/A |
NRXP Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -4.123 |
| Total Debt to Total Assets | 4.87 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -2.058 |